- Home
- MGRX vs LGVN Comparison
MGRX vs LGVN Comparison
Compare MGRX & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGRX | LGVN |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 12.7M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MGRX | LGVN |
|---|---|---|
| Price | $0.87 | $0.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | ★ 1.1M | 373.2K |
| Earning Date | 11-14-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $466,908.00 | ★ $1,437,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.52 | $0.49 |
| 52 Week High | $6.15 | $2.24 |
Technical Indicators
Market Signals| Indicator | MGRX | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 43.45 | 49.59 |
| Support Level | $0.65 | $0.49 |
| Resistance Level | $0.90 | $0.60 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 39.83 | 69.70 |
Price Performance
Historical ComparisonAbout MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.